After a patient receives Invega Sustenna (paliperidone palmitate), how soon should oral risperidone (Risperdal) be stopped?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Oral Risperidone Discontinuation After Invega Sustenna Initiation

Oral risperidone should be discontinued immediately on Day 1 when using the standard Invega Sustenna initiation regimen (234 mg deltoid on Day 1,156 mg on Day 8), as no oral supplementation is required with this loading dose strategy. 1

Standard Initiation Protocol

The FDA-approved initiation regimen for Invega Sustenna was specifically designed to achieve therapeutic paliperidone concentrations rapidly without requiring oral antipsychotic supplementation 1, 2, 3. The two deltoid injections (234 mg on Day 1 and 156 mg on Day 8) rapidly attain steady-state concentrations that fall within the therapeutic exposure range equivalent to 6-12 mg of oral extended-release paliperidone 1.

Key pharmacokinetic features supporting immediate discontinuation:

  • Drug release begins as early as Day 1 after injection 1
  • Maximum plasma concentrations occur at median 13 days 1
  • The initiation regimen maintains patients within therapeutic windows even at trough levels (Days 8 and 36) 1

Exception: High-Dose Risperidone Patients

For patients on risperidone ≥4 mg/day, consider continuing oral risperidone for at least 7 days after the first Invega Sustenna injection to bridge the transition and prevent subtherapeutic levels 4.

This bridging strategy is supported by real-world evidence showing:

  • Patients on ≥4 mg/day risperidone who received oral bridging (≥7 days) had statistically significant reductions in hospitalization days compared to non-bridged patients 4
  • The standard loading doses may not provide adequate initial coverage for patients previously stabilized on higher oral doses

Important Caveats

  • The FDA label does not explicitly recommend bridging, as the loading regimen was designed to eliminate this need 1
  • However, clinical outcomes data suggest bridging benefits specific high-dose patients 4
  • The optimal duration of bridging beyond 7 days remains unclear and requires further research 4

Practical Algorithm

For patients on risperidone <4 mg/day:

  • Stop oral risperidone on Day 1 when first Invega Sustenna injection is given

For patients on risperidone ≥4 mg/day:

  • Continue oral risperidone for 7-14 days after Day 1 injection
  • Taper is not necessary; abrupt discontinuation after bridge period is acceptable given overlapping paliperidone exposure

Switching from other oral antipsychotics:

  • Initiate Invega Sustenna the day after discontinuing the previous oral antipsychotic 2, 3
  • No overlap or bridging required

References

Related Questions

Can I administer Invega (paliperidone palmitate) long‑acting injectable to a patient who is only taking risperidone tablets?
If a patient previously on Invega Sustenna (paliperidone palmitate) stopped the injection and is now restarting it, should oral antipsychotic therapy be resumed as well?
What are the guidelines for combining oral Invega (paliperidone) with a long-acting injectable antipsychotic?
Can a patient who missed his Invega (paliperidone palmitate) injection and has been taking oral paliperidone for two weeks receive the next Invega injection the day after taking the oral dose?
If a patient is receiving a delayed 156 mg Invega (paliperidone palmitate) injection, should they continue oral risperidone for a week?
What anti‑inflammatory medications are safe for a heart‑transplant recipient, and what alternatives and monitoring precautions should be used?
For postpartum depression screening, should the PHQ‑2 or the Edinburgh Postnatal Depression Scale (EPDS) be used as the primary tool?
Should the patient hold low-dose aspirin (81 mg daily) prior to cataract surgery?
What is the recommended follow‑up and management for a 16‑year‑old male with an isolated left varicocele?
In a patient with multiple missing and decayed teeth, facial swelling, left‑sided oral pain, inflamed gums, and a black, cracked tooth, should I prescribe oral amoxicillin‑clavulanate (Augmentin) and also give intramuscular ceftriaxone (Rocephin), or is that excessive?
What withdrawal symptoms may occur when stopping Invega (paliperidone)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.